Clinical Trial News Archive - March 2024
March 4, 2024
March 5, 2024
- Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
- Semaglutide Reduces Severity of Common Liver Disease in People with HIV
- Dapivirine Vaginal Ring and Oral Pre-Exposure Prophylaxis Found Safe for HIV Prevention Throughout Pregnancy
March 6, 2024
- Long-Acting HIV Treatment Benefits Adults with Barriers to Daily Pill Taking and Adolescents with Suppressed HIV
- Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
- BlueRock Therapeutics Phase I Clinical Trial for Bemdaneprocel for Parkinson’s Disease Continues to Show Positive Trends at 18 Months
March 7, 2024
- MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
- New clinical study published demonstrates superiority of AI-algorithm guided melanoma diagnosis
- NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
March 8, 2024
- Silver Diamine Fluoride Topical Solution Halts Tooth Decay in Children
- Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
- U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab
March 9, 2024
March 10, 2024
- Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity
- More Than Two-Thirds of People with Atopic Dermatitis and Skin of Color Experienced Skin Improvement in a First-of-its-Kind Lebrikizumab Study
March 11, 2024
- Terns Pharmaceuticals Announces Orphan Drug Designation Granted To TERN-701 For The Treatment Of Chronic Myeloid Leukemia
- Viatris and Mapi Pharma Statement Regarding New Drug Application for GA Depot
- EmpowerPharm Awaits Phase II Clinical Trial On Ground Breaking Cannabidiol Treatment To Manage Social Anxiety Disorder
March 12, 2024
- New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements in Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
- NIH Opens Long COVID Trials to Evaluate Treatments for Autonomic Nervous System Dysfunction
- Delta-8-THC Use Reported by 11% of 12th Graders in 2023
- Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
March 13, 2024
- Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
- Ionis Announces Positive Results from Phase 2 Study of ION224, an Investigational Medicine Demonstrating Clinical Efficacy in the Treatment of NASH/MASH
- Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
- PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
- FDA Revises Letter of Authorization for the Emergency Use Authorization for Paxlovid
- Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
March 14, 2024
- Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
- Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
March 15, 2024
March 18, 2024
- Repurposed Drug Fenoprofen Shows Promise Against Endometriosis-Related Pain in Animal Model
- Positive Results from Phase 3 BouNDless Trial of Investigational ND0612 in People with Parkinson's Disease Experiencing Motor Fluctuation
March 19, 2024
- Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
- Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
- Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
March 20, 2024
- Bill & Melinda Gates Medical Research Institute Initiates Phase 3 Clinical Trial of Tuberculosis Vaccine Candidate
- Experimental Gene Therapy for Giant Axonal Neuropathy Shows Promise in NIH Clinical Trial
- Inflammation-Reducing Drug Minocycline Shows No Benefit For Dry Age-Related Macular Degeneration in NIH Trial
March 21, 2024
- Ibex Presents New Data from Multiple Studies Showcasing Accuracy of AI in Prostate, Breast and Gastric Cancer Diagnosis
- HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection (AMR) in Kidney Transplant Recipients
- Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
- Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment
March 22, 2024
March 25, 2024
- Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
- Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
- Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
- Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
- Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
March 26, 2024
March 29, 2024
Clinical trial results archive
- 2025
- January, February, March, April, May
- 2024
- January, February, March, April, May, June, July, August, September, October, November, December
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.